1 Sethi S, Fervenza FC. Membranoproliferative glomerulonephritis – a new look at an old entity. The New England journal of medicine. 2012;366(12):1119–31. doi: 10.1056/NEJMra1108178. PubMed PMID: 22435371.
2 McGrogan A, Franssen CF, de Vries CS. The incidence of primary glomerulonephritis worldwide: a systematic review of the literature. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association – European Renal Association. 2011;26(2):414–30. doi: 10.1093/ndt/gfq665. PubMed PMID: 21068142.
3 Gharavi AG, Kiryluk K, Choi M, Li Y, Hou P, Xie J, et al. Genome-wide association study identifies susceptibility loci for IgA nephropathy. Nature genetics. 2011;43(4):321–7. doi: 10.1038/ng.787. PubMed PMID: 21399633; PubMed Central PMCID: PMC3412515.
4 Gilg J, Rao A, Fogarty D. UK Renal Registry 16th annual report: chapter 1 UK renal replacement therapy incidence in 2012: national and centre-specific analyses. Nephron Clinical practice. 2013;125(1–4):1–27. doi: 10.1159/000360020. PubMed PMID: 24662165.
5 Collins AJ, Foley RN, Chavers B, Gilbertson D, Herzog C, Ishani A, et al. US Renal Data System 2013 Annual Data Report. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2014;63(1 Suppl):A7. doi: 10.1053/j.ajkd.2013.11.001. PubMed PMID: 24360288.
6 Hassanien AA, Al-Shaikh F, Vamos EP, Yadegarfar G, Majeed A. Epidemiology of end-stage renal disease in the countries of the Gulf Cooperation Council: a systematic review. JRSM Short Rep. 2012;3(6):38. doi: 10.1258/shorts.2012.011150. PubMed PMID: 22768372; PubMed Central PMCID: PMCPMC3386663.
7 Ribi C, Trendelenburg M, Gayet-Ageron A, Cohen C, Dayer E, Eisenberger U, et al. The Swiss Systemic lupus erythematosus Cohort Study (SSCS) – cross-sectional analysis of clinical characteristics and treatments across different medical disciplines in Switzerland. Swiss medical weekly. 2014;144:w13990. doi: 10.4414/smw.2014.13990. PubMed PMID: 25115978.
8 Pedchenko V, Bondar O, Fogo AB, Vanacore R, Voziyan P, Kitching AR, et al. Molecular architecture of the Goodpasture autoantigen in anti-GBM nephritis. The New England journal of medicine. 2010;363(4):343–54. doi: 10.1056/NEJMoa0910500. PubMed PMID: 20660402; PubMed Central PMCID: PMCPMC4144421.
9 Madaio MP, Harrington JT. The diagnosis of glomerular diseases: acute glomerulonephritis and the nephrotic syndrome. Arch Intern Med. 2001;161(1):25–34. PubMed PMID: 11146695.
10 Yata N, Ikeda M, Ishikura K, Hataya H, Matsuyama T, Banba M, et al. Typical MPGN with few urinary abnormalities. American journal of kidney diseases: the official journal of the National Kidney Foundation. 2004;43(5):918–22. PubMed PMID: 15112183.
11 Papista C, Berthelot L, Monteiro RC. Dysfunctions of the Iga system: a common link between intestinal and renal diseases. Cell Mol Immunol. 2011;8(2):126-34. doi: 10.1038/cmi.2010.69. PubMed PMID: 21278767; PubMed Central PMCID: PMCPMC4003139.
12 Obrisca B, Ismail G, Jurubita R, Baston C, Andronesi A, Mircescu G. Antiphospholipase A2 Receptor Autoantibodies: A Step Forward in the Management of Primary Membranous Nephropathy. BioMed research international. 2015;2015:249740. doi: 10.1155/2015/249740. PubMed PMID: 26576418; PubMed Central PMCID: PMC4630372.
13 Beck LH Jr, Bonegio RG, Lambeau G, Beck DM, Powell DW, Cummins TD, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. The New England journal of medicine. 2009;361(1):11–21. doi: 10.1056/NEJMoa0810457. PubMed PMID: 19571279; PubMed Central PMCID: PMC2762083.
14 Murtas C, Ghiggeri GM. Membranous glomerulonephritis: histological and serological features to differentiate cancer-related and non-related forms. Journal of nephrology. 2016.
doi: 10.1007/s40620-016-0268-7. PubMed PMID: 26810113.
15 Kim YG, Choi YW, Kim SY, Moon JY, Ihm CG, Lee TW, et al. Anti-Phospholipase A2 Receptor Antibody as Prognostic Indicator in Idiopathic Membranous Nephropathy. American journal of nephrology. 2015;42(3):250-7. doi: 10.1159/000440983.
PubMed PMID: 26484659.
16 Hofstra JM, Beck LH, Jr., Beck DM, Wetzels JF, Salant DJ. Anti-phospholipase A(2) receptor antibodies correlate with clinical status in idiopathic membranous nephropathy. Clinical journal of the American Society of Nephrology : CJASN. 2011;6(6):1286–91.
doi: 10.2215/CJN.07210810. PubMed PMID: 21474589;
PubMed Central PMCID: PMC3109923.
17 Radice A, Trezzi B, Maggiore U, Pregnolato F, Stellato T, Napodano P, et al. Clinical usefulness of autoantibodies to M-type phospholipase A2 receptor (PLA2R) for monitoring disease activity in idiopathic membranous nephropathy (IMN). Autoimmunity reviews. 2016;15(2):146-54. doi: 10.1016/j.autrev.2015.10.004.
PubMed PMID: 26527329.
18 Beck LH Jr, Fervenza FC, Beck DM, Bonegio RG, Malik FA, Erickson SB, et al. Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. Journal of the American Society of Nephrology: JASN. 2011;22(8):1543–50.
doi: 10.1681/ASN.2010111125. PubMed PMID: 21784898; PubMed Central PMCID: PMC3148709.
19. Gupta G, Fattah H, Ayalon R, Kidd J, Gehr T, Quintana LF, et al. Pre-transplant phospholipase A2 receptor autoantibody concentration is associated with clinically significant recurrence of membranous nephropathy post-kidney transplantation. Clinical transplantation. 2016;30(4):461-9. doi: 10.1111/ctr.12711. PubMed PMID: 26854647.
20 Ishimoto T, Shimada M, Araya CE, Huskey J, Garin EH, Johnson RJ. Minimal change disease: a CD80 podocytopathy? Semin Nephrol. 2011;31(4):320–5. doi: 10.1016/j.semnephrol.2011.06.002.
PubMed PMID: 21839364.
21 Yu CC, Fornoni A, Weins A, Hakroush S, Maiguel D, Sageshima J, et al. Abatacept in B7-1-positive proteinuric kidney disease. The New England journal of medicine. 2013;369(25):2416-23. doi: 10.1056/NEJMoa1304572. PubMed PMID: 24206430; PubMed Central PMCID: PMCPMC3951406.
22. Delville M, Baye E, Durrbach A, Audard V, Kofman T, Braun L, et al. B7-1 Blockade Does Not Improve Post-Transplant Nephrotic Syndrome Caused by Recurrent FSGS. Journal of the American Society of Nephrology : JASN. 2016;27(8):2520–7. doi: 10.1681/ASN.2015091002. PubMed PMID: 26701979; PubMed Central PMCID: PMCPMC4978058.
23 Global KDI, Group. OKGW. KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney inter. Suppl. 2012;2:139–274.
24 Isbel NM. Glomerulonephritis – management in general practice. Aust Fam Physician. 2005;34(11):907–13. PubMed PMID: 16299623.
25 Floege J, Rauen T, Eitner F. Intensive Supportive Care plus Immunosuppression in IgA Nephropathy. The New England journal of medicine. 2016;374(10):992–3. doi: 10.1056/NEJMc1600141. PubMed PMID: 26962736.
26 Dahan K, Debiec H, Plaisier E, Cachanado M, Rousseau A, Wakselman L, et al. Rituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up. Journal of the American Society of Nephrology: JASN. 2016.
doi: 10.1681/ASN.2016040449. PubMed PMID: 27352623.
27 Kattah AG, Fervenza FC, Roccatello D. Rituximab-based novel strategies for the treatment of immune-mediated glomerular diseases. Autoimmunity reviews. 2013;12(8):854–9.
doi: 10.1016/j.autrev.2012.09.002. PubMed PMID: 23000633.
28 Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. The New England journal of medicine. 2010;363(3):221–32. doi: 10.1056/NEJMoa0909905. PubMed PMID: 20647199; PubMed Central PMCID: PMC3137658.
29 Kattah AG, Fervenza FC. Rituximab: emerging treatment strategies of immune-mediated glomerular disease. Expert review of clinical immunology. 2012;8(5):413-21. doi: 10.1586/eci.12.26.
PubMed PMID: 22882216.
30 Cacoub P, Delluc A, Saadoun D, Landau DA, Sene D. Anti-CD20 monoclonal antibody (rituximab) treatment for cryoglobulinemic vasculitis: where do we stand? Annals of the rheumatic diseases. 2008;67(3):283–7. doi: 10.1136/ard.2006.065565. PubMed PMID: 17644544.
31 Saadoun D, Resche-Rigon M, Sene D, Perard L, Karras A, Cacoub P. Rituximab combined with Peg-interferon-ribavirin in refractory hepatitis C virus-associated cryoglobulinaemia vasculitis. Annals of the rheumatic diseases. 2008;67(10):1431–6.
doi: 10.1136/ard.2007.081653. PubMed PMID: 18178690.
32 Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, Sanchez-Guerrero J, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis and rheumatism. 2012;64(4):1215–26. doi: 10.1002/art.34359. PubMed PMID: 22231479.
33 Fervenza F. Rituximab in Progressive IgA Nephropathy. ClinicalTrialsgov.
34 Jäger C, Kononowa N, Kim MJ. Néphropathie à immunoglobulines A. Forum Med Suisse. 2017;17(11):252–257.
35 McAdoo S. Ofatumumab for B Cell depletion therapy in patients with systemic lupus erythematosus who are intolerant of rituximab. Abstract ISN.
36 McAdoo SP, Bedi R, Tarzi R, Griffith M, Pusey CD, Cairns TD. Ofatumumab for B cell depletion therapy in ANCA-associated vasculitis: a single-centre case series. Rheumatology. 2016. doi: 10.1093/rheumatology/kew199. PubMed PMID: 27094598.
37 Maisonneuve P, Agodoa L, Gellert R, Stewart JH, Buccianti G, Lowenfels AB, et al. Distribution of primary renal diseases leading to end-stage renal failure in the United States, Europe, and Australia/New Zealand: results from an international comparative study. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2000;35(1):157–65. doi: 10.1016/S0272-6386(00)70316-7. PubMed PMID: 10620560.
38 Haider DG, Masghati S, Goliasch G, Mouhieddine M, Wolzt M, Fuhrmann V, et al. Kidney biopsy results versus clinical parameters on mortality and ESRD progression in 2687 patients with glomerulonephritis. European journal of clinical investigation. 2014;44(6):578–86. doi: 10.1111/eci.12274. PubMed PMID: 24749685.